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Abstract Objective: Compare the electroencephalo-
graphic (EEG) and cardiovascular effects of tobacco
smoking and nasal nicotine in the same subjects.
Methods: Eleven volunteer smokers were studied after
>10 h of overnight tobacco deprivation. Quantitative
EEG was used to measure brain electrical changes pro-
duced by four different treatments. Each subject smoked
a low (0.08 mg) and average nicotine (1 mg) yield ciga-
rette on one test day and received placebo and nicotine
nasal spray (0.5 mg/spray) on a second day in a coun-
terbalanced design. EEG activity was measured from 16
scalp electrodes and analyzed as delta, theta, alpha1,
alpha2, beta1, and beta2 frequency bands. Heart rate
(HR), blood pressure (BP), and plasma venous nicotine
concentrations (VNC) were monitored during both ses-
sions. EEG data from all 16 channels at each of six
frequencies were compared over 10 min using repeated
measures ANOVA analysis. Changes in HR, BP, and
VNC from baseline were compared using ANOVA fol-
lowed by post hoc Scheffe’s test.
Results: Smoking an average nicotine delivery cigarette
resulted in highly significant decreases in alpha1 activity,
significant increases in alpha2 activity, and significant
increases in both HR and VNC compared to all other
conditions.
Conclusion: When smokers are allowed to pace them-
selves, cigarette smoking is far more effective than nasal
nicotine in activating the EEG and increasing HR and
VNC. This lack of equivalent physiological effects may
explain the low success rate when nicotine nasal spray is
used by those trying to quit smoking.
Keywords Brain Æ Electrophysiology Æ Nicotine Æ
Tobacco
Introduction
A large body of basic neuroscience data indicates to-
bacco addiction involves nicotine [1], which releases the
neurotransmitter dopamine (DA), similar to other drugs
of abuse [2]. Nicotine nasal spray is a delivery system,
which allows more rapid increases in venous blood levels
of nicotine than with other nicotine replacement thera-
pies. However, treatment success is only about 18% of
smokers that remain abstinent after one year with nic-
otine nasal spray versus 8% with placebo [3]. The high
blood levels of nicotine achieved rapidly upon smoking a
cigarette probably account for the greater objective and
subjective effects when compared to more slowly
released forms of nicotine [4, 5].
In the present study, quantitative EEG was used to
measure brain electrical changes produced by four drug
conditions: a low nicotine yield cigarette, an average
nicotine yield cigarette, commercially available nicotine




The study protocol was approved by the University of Michigan
Institutional Review Board. Twenty-five healthy adult male (13)
and female (12) cigarette smokers (>15 to 40 cigarettes per day),
ranging in age from 18–44 years, and free from medication use
(except for females taking oral contraceptives) were recruited
through advertisements placed on the University of Michigan
Central Campus and in the University of Michigan Hospitals.
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Subjects with any physical or mental disease were excluded based
on medical history, physical exam, or serum electrolyte, liver en-
zymes, creatinine, BUN, and CBC results. Those with a history of
psychotic, manic or bipolar disorder were also excluded. Subjects
who had a history of psychoactive substance abuse disorder within
the past six months, or who revealed evidence of recent use of
abused substances in a urine toxicology screen were excluded.
Persons who were currently taking medications (except for females
taking oral contraceptives) and those who had taken antidepres-
sant, anxiolytic, or antipsychotic medications within the past
6 months were excluded. Candidates who seemed eligible on the
basis of a preliminary telephone screen were invited to a screening
interview, at which time the study was explained and informed
consent obtained. A brief physical examination, including height,
weight, blood pressure, and heart rate was conducted. Laboratory
tests on blood including complete blood count, electrolytes, liver
function tests, urinalysis and urine toxicology screen were obtained
for screening purposes. Patients were also assessed for degree of
nicotine dependence using the Fagerström Test for Nicotine De-
pendence (FTND) [6].
On the day of a test session, each subject reported to the testing
laboratory at 0800. A Vitalograph Breath CO monitor (Vitalo-
graph USA, Lenexa, Kansas) was used to determine the parts per
million (ppm) of exhaled carbon monoxide (CO). Alveolar
CO<10 ppm was one of the criteria of tobacco abstinence.
Experimental design
Subjects who passed screening procedures were scheduled for two
testing sessions on different days at least one week apart. None of
the subjects and only one of the investigators knew the order of the
treatments. During one test session, subjects smoked a low nicotine
yield (0.08 mg) cigarette followed 1 h later by an average nicotine
yield (1.0 mg) cigarette. During the other test session the subject
received placebo nasal spray followed by nicotine nasal spray. The
order of testing sessions (cigarettes versus sprays) was randomized.
Prior to both study sessions, subjects were asked to abstain from
cigarette smoking overnight >10 h before reporting for study the
next morning. They were also asked not to drink any alcohol for
one day prior to the study session, and not to drink any caffeinated
beverages on the morning of the study.
Both research cigarettes were kindly provided by Philip Morris,
U.S.A. The nicotine nasal spray was delivered using a commercially
available nicotine spray (McNeil Laboratories), which provides a
metered dose of nicotine solution equivalent to 0.5 mg per spray.
The active placebo oleoresin of pepper spray was provided by Dr.
K.O. Fagerström. An attempt was made to acclimate the subjects
to the nicotine spray by showing them the correct method of ad-
ministering the spray. Subjects were also given the nicotine spray to
practice with and use at home prior to the study sessions. If subjects
were not able to tolerate the entire dose of nicotine spray, they
received a lower dose. The number of sprays administered varied
from two to a maximum of six, as tolerated. The placebo spray
contained oleoresin of black pepper that partially simulates the
nasal irritation of nicotine.
A heparin lock was placed in a forearm vein to facilitate blood
drawing. Immediately prior to smoking a cigarette or receiving
nasal spray, a 5 ml baseline blood sample was obtained. Another
sample was obtained 10 min following the initiation of smoking or
administration of nasal spray. Blood samples were placed on ice,
centrifuged, and the plasma stored at –20C until analysis. Samples
were analyzed for nicotine concentration using the method of
Hariharan et al. [7].
The subjects rested in a supine position in a comfortable recliner
in the experimental smoking room. The EEG procedure utilized 16
cortical sites for monopolar recordings linked to A1and A2 as the
reference lead per the 10–20 International System [8]. An electrode
cap (Electrode Cap International, Eaton, OH, USA) was placed on
the subject’s head with Grass electrode paste applied to each
electrode. Electrode salt paste was used to keep electrode resistance
below 5000 ohms to both ear lobes as reference. The subjects
smoked, at their usual rate and depth of inhalation, a low-nicotine
cigarette for 5 min maximum, or received placebo nasal spray (2–6
sprays). EEG recordings (with eyes closed) were taken before and
at 3, 6, and 10 min from the start of smoking the low-nicotine
cigarette or receiving the placebo nasal spray. One hour later, the
subject smoked an average-nicotine cigarette for 5 min or received
nicotine nasal spray (2–6 sprays). EEG recordings were again ob-
tained at baseline, 3, 6, and 10 min. HR and BP were monitored at
the same time as the EEG.
Data analysis
The EEG recordings taken from F7, F8, T3, T4, T5, T6,
Fp1, Fp2, F3, F4, C3, C4, P3, P4, O1, and O2 were re-
corded on channels 1–16 of a Grass electroencephalo-
graph (Model 8–24D). Computer analysis of the
electrophysiological data was completed offline by the
software package RHYTHM 7.1 (Stellate Systems,
Quebec, Canada) utilizing a Zenith 386/25 microcom-
puter. Analog to digital conversion of the EEG signal
was done for the maximum number of artifact-free ep-
ochs in each recording period. The digitized data un-
derwent fast Fourier transformation to determine the
frequency characteristics in each of the 6 bandwidths; 1–
3.75 Hz (delta), 4–7.5 Hz (theta), 7.75–10 Hz (alpha1),
10.25–12.5 Hz (alpha2), 12.75–20 Hz (beta1), and 20.25–
31 Hz (beta2). Analyses of the EEG data were accom-
plished using a within subjects ANOVA for repeated
measures. Absolute EEG amplitudes, within the six
frequency ranges, were compared across the four drug
conditions at baseline, 3, 6, and 10 min using the PROC
MIXED program in SAS Version 8.1 for Windows (SAS
Institute Inc., Cary, NC, USA). Post hoc comparisons
were conducted using contrasts; alpha was adjusted to
0.0083. The HR, BP, and nicotine plasma concentration
differences were compared across the four drug condi-
tions using ANOVA followed by post hoc Scheffe’s test.
Figure 1 depicts the trial design.
Results
The selected study population consisted of 7 male and 6
female subjects who completed both days of testing.
However, baseline nicotine blood levels indicated that
two female subjects had unacceptably high baseline
nicotine levels (>10 ng/ml), indicating these two vol-
unteers were probably noncompliant. These subjects
were removed from the data analyses. The results are
based on the remaining 11 subjects (7 M, 4 F). The
mean age for male subjects was 26.3 years (19–36 years),
and for female subjects 26.3 years (18–32 years). Eight
subjects were Caucasian, 1 African-American, 1 Korean,
and 1 East-Indian. The average Fagerström Test for
Nicotine Dependence score was 3.6 (range 0–6); average
score for men was 3.4 (range 0–6) and for women 4.0
(range 2–5).
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Plasma venous nicotine levels
ANOVA followed by post hoc Scheffe’s test revealed
significantly higher nicotine concentrations at 10 min
following the smoking of an average nicotine yield cig-
arette. In this small sample, smoking an average nicotine
cigarette resulted in much higher nicotine concentrations
in men than women, probably reflecting differences in
smoking style. Interestingly, the administration of nic-
otine nasal spray did not cause equivalent elevations of
plasma nicotine in most subjects. Smoking an average
nicotine yield cigarette produced the largest increase in
plasma nicotine in both genders, as illustrated in Fig. 2.
In view of the small N, the gender differences were not
significant and the data were pooled. Both the low nic-
otine yield cigarette and the nicotine nasal spray pro-
duced relatively minor increases in plasma nicotine
levels.
Electroencephalographic effects
Within subjects repeated measures ANOVA revealed an
interaction between drug condition (average nicotine
cigarette, low nicotine cigarette, nicotine nasal spray,
placebo nasal spray) and time (3, 6, and 10 min), which
was statistically significant (p=0.0083) in most channels,
especially within the alpha1 frequency range (see
Table 1. There was a significant decrease in alpha1 ac-
tivity at 3 min across all 16 channels and a significant
increase in alpha2 activity at 10 min in 8 channels, fol-
lowing the smoking of an average-nicotine cigarette. The
reduced amplitude seen in the alpha1 frequency band at
3 min was especially pronounced in channels 5, 6, and 9–
14 (T5, T6, F3, F4, C3, C4, P3 and P4). The increased
amplitude seen in the alpha2 frequency band at 10 min
occurred mostly in channels 1, 2, and 8 (F7, F8, and
Fp2). Figure 3 summarizes the statistically significant
differences in alpha1 and alpha2 activity seen at 3 and
10 min, respectively. Smoking an average nicotine yield
cigarette (ANC) produced a marked decrease in alpha1
activity with recovery to baseline in 10 min. In contrast,
the marked increase in alpha2 activity was maximal
Fig. 1. Experimental design. Symbols used in this and/or the
following figures: PRE, before any treatment >10 h overnight
tobacco deprivation; LNC, after smoking a low nicotine yield
cigarette; ANC, after smoking an average nicotine yield cigarette;
NSY, after nicotine nasal spray; PSY, after placebo oleoresin of
pepper spray; VNC, plasma venous nicotine concentrations
Fig. 2. Effects of cigarette
smoking and nicotine nasal
spray on plasma nicotine levels.




10 min after ANC. Both low nicotine yield cigarettes
(LNC) and nicotine nasal spray (NSY) produced similar
but much smaller changes. The placebo nasal spray was
relatively ineffective compared to the other treatments.
Differences found in the delta, theta, and beta1 frequency
bands, among the four drug conditions, were not as
pronounced or as consistent as those seen in the alpha1
and alpha2 frequency bands. There were no statistically
significant differences found in the beta2 band among
any of the drug conditions.
Effects on heart rate
Repeated measures ANOVA followed by post hoc
Scheffe’s test revealed significantly higher HR after
smoking an average nicotine yield cigarette at 3, 6, and
10 min. The mean change in heart rate from baseline
(DHR) over time is plotted in Fig. 4. The differences in
HR after smoking a low nicotine yield cigarette and
nicotine nasal spray were not statistically significant.
The peak HR increases occurred at 3 min after smoking
or nicotine nasal spray. Mean increases±SD in HR
from baseline to 3 min after smoking an average and
low nicotine yield cigarette and after receiving nicotine
and placebo nasal spray were 19.9±8.9, 6.9±8.3,
8.0±7.2 and 0.8±4.1 beats/min, respectively. The
maximum HR recorded after smoking an average nic-
otine yield cigarette was 116 beats/min. Smoking an
average nicotine yield cigarette (ANC) produced the
greatest mean change in HR, whereas a low nicotine
yield cigarette (LNC) and nicotine nasal spray (NSY)
produced similar, small increases in HR. The placebo
oleoresin of pepper had no effect. Surprisingly, there
were no statistically significant differences in BP found
between any of the nicotine conditions.
Table 1. Statistically significant
(p=0.0083) differences between
smoking an average nicotine
yield cigarette and all other drug
conditions: low nicotine yield
cigarette (L), nicotine nasal
spray (N), and placebo nasal
spray (P)
EEG channel Delta Theta Alpha1 Alpha2 Alpha2
1–3.75 Hz 4–7.5 Hz 7.75–10 Hz 10.25–12.5 Hz 10.25–12.5
10 min decrease 3 min decrease 3 min decrease 6 min increase 10 min increase
1 L L, N L, N, P
2 N L, N P L, N, P
3 L, N N, P N, P
4 N P P
5 L L L, N, P
6 N L, N, P
7 N P L, P
8 L, N P L, N, P
9 L N L, N, P P L, P
10 L N L, N, P P P
11 N L, N, P
12 L N L, N, P
13 N, P L, N, P
14 L N, P L, N, P
15 L, N
16 L L
Fig. 3. Effects of cigarette
smoking and nicotine nasal
spray on changes in EEG alpha
frequency. The EEG alpha
changes for two channels
(alpha1 channel 15 and alpha2
channel 8) are plotted after
various treatments. Statistically
significant differences from




The principal finding of this study was that smoking an
average nicotine yield cigarette resulted in significantly
different physiological effects in comparison with self-
paced administration of nicotine nasal spray. Smoking
an average nicotine cigarette was accompanied by a shift
to higher brain wave frequencies; most notably a shift
from alpha1 to alpha2 activity across 10 min. Further-
more, smoking an average nicotine yield cigarette re-
sulted in significant increases in both heart rate and
plasma nicotine concentrations as compared to nasal
nicotine administration.
It has been well documented that the administration
of nicotine and its deprivation in smokers results in
changes in EEG activity [9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19]. Various periods of smoking deprivation have
resulted in increased lower frequency bands power [14,
15, 18, 19], while tobacco smoking produces a shift to
higher frequencies in deprived smokers [9, 10, 11, 12, 13,
14, 16, 17]. The current investigation corroborates ear-
lier studies that tobacco smoking causes a shift from
lower to higher brain wave activity.
Smoking tobacco has consistently been shown to in-
crease heart rate [9, 10, 11, 20, 21, 22]. Smoking an av-
erage nicotine yield cigarette resulted in significantly
higher heart rates in our subjects, which corresponded to
significantly higher concentrations of plasma nicotine
when compared with either low nicotine yield cigarettes
or nicotine nasal spray. This is not surprising since in-
creases in heart rate are correlated with increasing
plasma nicotine levels [11, 20, 21].
Tobacco smokers obtain far more nicotine by smoke
inhalation than they are able to tolerate by nasal spray.
The venous plasma nicotine levels observed in our study
following the administration of nicotine nasal spray are
lower than those reported previously with plasma levels
between 5 and 12 ng/ml [23]. When given as a single
1 mg dose, similar to the amount of nasal nicotine de-
livered in the current investigation, mean peak venous
nicotine concentrations of 8.1 ng/ml were seen, which
occurred at a peak rise time of 11.5 min [3]. The lower
plasma nicotine levels in our population were due to the
smokers’ strong dislike for the nasal spray. Subjects in
our sample found the nicotine nasal spray very irritating
and obviously did not use it optimally. This is consistent
with the literature, which indicates that subjects often
complain of nasal irritation, throat irritation, sneezing,
runny nose, watery eyes, and coughing [3, 24, 25]. Ad-
verse effects significantly contribute to the lack of pop-
ularity of this preparation within the general population
of those trying to quit smoking, especially when emo-
tional support is not available as it is during clinical
trials.
The difference in EEG effects found between nasal
nicotine and average nicotine yield cigarettes in the
present study are probably due to differences in total
nicotine intake. Changes in EEG activity are correlated
with plasma nicotine levels [11, 26]. Kadoya et al. [11]
found a statistically significant decrease in delta activity
with an increase in venous plasma nicotine of 15 ng/ml
or more, while a decrease in alpha1 and increase in beta
activity were found with plasma nicotine increases of
10 ng/ml or more.
While this experimental design allowed comparison
of physiological parameters between low nicotine and
average nicotine yield cigarettes, and also between pla-
cebo and nicotine nasal spray on the same experimental
day, for each procedure the comparisons between ciga-
rettes and nasal spray were not conducted on the same
day. Baseline conditions did not differ significantly be-
tween the days on which subjects received cigarettes or
nasal spray. A major limitation of this study is the lack
of predetermined dose of either the cigarettes or nasal
spray (i.e., the subjects were allowed to decrease their
dose if intolerable). However, this study design reflects
what patients do in ‘‘real-life’’ situations. Nicotine nasal
spray would probably be more effective clinically if each
smoker was told he or she must try to gradually increase
the number of sprays to a maximum equivalent to the
absorbed dose of nicotine they achieve by smoking a
cigarette. Reinforcement and addiction to nicotine are
thought to be caused by rapid delivery of nicotine to the
brain [27]. This study provides direct evidence that the
higher blood levels of nicotine achieved rapidly upon
smoking a cigarette account for the greater objective and
subjective effects when compared to more slowly re-
leased forms of nicotine.
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